IOVA Company Profile and Key Details

Q: Who are the executives of IOVA?

Ms. Sara PellegrinoVice President of Investor Relations & PRMr. Jean-Marc Bellemin M.B.A.Chief Financial Officer, Principal Accounting Officer & TreasurerDr. Raj K. Puri M.D., Ph.D.Executive Vice President of Regulatory Strategy & Translational MedicineMs. Tracy WintonSenior Vice President of HRMr. Madan JagasiaExecutive Vice President of Medical AffairsDr. Igor P. BilinskyChief Operating OfficerMr. Brian Shew M.B.A.Senior Vice President & Head of Digital and Information TechnologyMr. Howard B. Johnson M.B.A.Chief Bus. OfficerDr. Frederick G. Vogt Esq., J.D., Ph.D.Interim Chief Executive Officer, Pres, Gen. Counsel & Corporation Sec.Mr. James Ziegler M.B.A.Executive Vice President of CommercialDr. Friedrich Graf Finckenstein M.D.Chief Medical Officer

NASDAQ : IOVA

Iovance Biotherapeutics

$3.83

0.05+1.32%

At Close 4:00 PM

57.74

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Iovance Biotherapeutics, Inc. (IOVA) stock surged +1.32%, trading at $3.83 on NASDAQ, up from the previous close of $3.78. The stock opened at $4.17, fluctuating between $3.79 and $4.35 in the recent session.

Stock Snapshot

3.78

Prev. Close

1.27B

Market Cap

3.785

Day Low

-3.22

P/E Ratio

-1.19

EPS (TTM)

-1.5

Cash Flow per Share

4.17

Open

331.69M

Number of Shares

4.35

Day High

83.9%

Free Float in %

2.28

Book Value

45.9M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 25, 2026	4.17	4.35	3.78	3.83	46.03M
Feb 24, 2026	3.30	3.90	3.21	3.78	69.32M
Feb 23, 2026	2.87	2.99	2.81	2.89	11.73M
Feb 20, 2026	2.83	2.89	2.75	2.87	9.17M
Feb 19, 2026	2.72	2.87	2.68	2.85	8.59M
Feb 18, 2026	2.62	2.76	2.60	2.72	6.99M
Feb 17, 2026	2.55	2.64	2.47	2.62	6.57M
Feb 13, 2026	2.57	2.65	2.55	2.57	6.39M
Feb 12, 2026	2.66	2.68	2.50	2.52	5.81M
Feb 11, 2026	2.58	2.60	2.48	2.60	6.95M
Feb 10, 2026	2.61	2.73	2.57	2.60	6.2M
Feb 09, 2026	2.52	2.61	2.46	2.60	6.81M
Feb 06, 2026	2.42	2.58	2.42	2.53	6.88M
Feb 05, 2026	2.40	2.46	2.25	2.36	15.51M
Feb 04, 2026	2.65	2.71	2.43	2.44	12.21M
Feb 03, 2026	2.62	2.77	2.57	2.64	9.95M
Feb 02, 2026	2.56	2.66	2.47	2.61	11.07M
Jan 30, 2026	2.60	2.68	2.53	2.55	8.99M
Jan 29, 2026	2.75	2.84	2.62	2.63	10.65M
Jan 28, 2026	2.99	3.03	2.73	2.75	11.25M

Contact Details

San Carlos, CA 94070

United States

https://www.iovance.com 650 260 7120

About Company

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Universit� de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Stock Peers

ARGX

-23.33-2.78%

argenx SE$816.95 REGN

12.09+1.57%

Regeneron Pharmaceuticals, Inc.$784.28 UTHR

61.67+13.03%

United Therapeutics Corporation$535.10 VRTX

-4.38-0.90%

Vertex Pharmaceuticals Incorporated$483.05 MDGL

-4.99-1.13%

Madrigal Pharmaceuticals, Inc.$435.01 PRAX

4.84+1.41%

Praxis Precision Medicines, Inc.$347.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.49-1.65%

Alnylam Pharmaceuticals, Inc.$327.36 KRYS

5.6+2.10%

Krystal Biotech, Inc.$272.50 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) closed at $3.83 USD, gaining $0.05 (1.32%) from the previous close of $3.78. The stock is currently mid-range between its 52-week high and low $1.64 and $5.88. With a market capitalization of about $1.27 billion, Iovance Biotherapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.76). Key stats such as the average daily volume over the past year has been around 11.14 million shares, trading with heavier-than-usual volume. Headquartered in San Carlos, CA, Iovance Biotherapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Frederick G. Vogt, the company employs approximately 838 people and listed since October 15, 2010. Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 39.37%, SMA50 45.24%, SMA200 65.28%). The stock’s 14-day RSI is 79.85 (overbought), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.09% below its high and over 133.75% above its low. Average 10-day trading volume of 22.63 million shares is significantly above the 3-month average of 12.32 million, indicating heightened recent market interest.

Valuation Metrics

Iovance Biotherapeutics, Inc. trades at a P/E ratio of -3.53, slightly below the S&P 500 average, with a price-to-sales ratio of 5.1 and a price-to-book ratio of 2.0 suggesting the stock is closer to book value. The P/FCF stands at -3.8, also below market averages.

Dividend & Fair Value

Iovance Biotherapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.20. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Iovance Biotherapeutics, Inc. generated EPS of -$1.12 over the past year. Five-year average earnings growth is 10.23%. The latest quarter delivered EPS of -$0.25. The next quarter is forecast at -$0.15. Next year's EPS is expected at $26.57. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 9 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $32.00 to $5.00. The high target offers 735.51% upside. The low target suggests 30.55% downside. The mean target is $16.73. This offers 336.81% upside. Iovance Biotherapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -13.56%. The prior quarter beat by 13.79%. Over the last six quarters, Apple has recorded several small beats. These include -8.11% in August 08, 2024.

Shareholding & Insider Activity

Iovance Biotherapeutics, Inc. has 361.85 million shares outstanding. The public float is 303.63 million shares, elevated short interest at 21.64% of float. This equals 67.71 million shares. The short ratio is 2.93 days. Institutional investors hold 69.59% of the float. Insiders own 0.36%. Rothbaum Wayne P. holds 28.07 million shares, BRISTOL INVESTMENT FUND LTD has 3.87 million shares and Ayer Capital Management, LP has 2.82 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Iovance Biotherapeutics generated $1.19M in revenue, or $0.01 per share. Gross margin was -2686.12%, operating margin -38734.99%, and net profit margin -37345.42%. Returns are negative, with ROA at -56.90% and ROE at -75.95%.
On valuation metrics, Iovance Biotherapeutics trades at a P/E of -3.53, P/S of 5.10 and P/B of 2.00. The current ratio is 3.41 and quick ratio is 3.00. Operationally, the company’s inventory turnover is 2.97 and cash conversion cycle is 146.03 days. Debt-to-equity is 0.07, supported by a cash flow-to-debt ratio of -5.76.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Iovance Biotherapeutics posted revenue of $1.19M, down slightly from $0.00 in the prior quarter. Gross profit was - $31.94M (margin -2686.12%). Operating income was - $460.56M (margin -38735.0%). Net income was- $444.04M (EPS - $1.89).
The company ended the quarter with $279.87M in cash and short-term investments, a total debt of $75.86M, and net debt of - $39.03M. Total assets were $780.35M, with equity of $584.61M. Financials further reflected weakness, with operating cash flow of - $361.82M, free cash flow of - $384.11M, and capital expenditures of - $22.29M.

Price Forecast & Outlook

Our AI price prediction model suggests that Iovance Biotherapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.31%, with price expected at $3.88 by March 11, 2026, within a range of $3.68 to $4.07 3-Month Outlook: Projected fall of -33.16%, reaching $2.56 by May 25, 2026, with a range of $2.37 to $2.75. 1-Year Outlook: Projected gain of 113.32%, with price at $8.17 by February 25, 2027, within a range of $0.00 to $6.65.

Key Takeaways

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares are down -10.62% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Iovance Biotherapeutics, Inc. trading at a premium to the broader market with a P/E of -3.53. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $23.91, suggesting 524.28% upside. Our AI forecast model points to short-term strength (1.31% over two weeks), a medium-term fall (-33.16% over three months), and a longer-term gain (113.32% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Iovance Biotherapeutics, Inc. (IOVA) stock price?

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) stock price is $3.83 in the last trading session. During the trading session, IOVA stock reached the peak price of $4.35 while $3.79 was the lowest point it dropped to. The percentage change in IOVA stock occurred in the recent session was 1.32% while the dollar amount for the price change in IOVA stock was $0.05.

IOVA's industry and sector of operation?

The NASDAQ listed IOVA is part of Biotechnology industry that operates in the broader Healthcare sector. Iovance Biotherapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of IOVA?

Ms. Sara Pellegrino
Vice President of Investor Relations & PR
Mr. Jean-Marc Bellemin M.B.A.
Chief Financial Officer, Principal Accounting Officer & Treasurer
Dr. Raj K. Puri M.D., Ph.D.
Executive Vice President of Regulatory Strategy & Translational Medicine
Ms. Tracy Winton
Senior Vice President of HR
Mr. Madan Jagasia
Executive Vice President of Medical Affairs
Dr. Igor P. Bilinsky
Chief Operating Officer
Mr. Brian Shew M.B.A.
Senior Vice President & Head of Digital and Information Technology
Mr. Howard B. Johnson M.B.A.
Chief Bus. Officer
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Interim Chief Executive Officer, Pres, Gen. Counsel & Corporation Sec.
Mr. James Ziegler M.B.A.
Executive Vice President of Commercial
Dr. Friedrich Graf Finckenstein M.D.
Chief Medical Officer

How IOVA did perform over past 52-week?

IOVA's closing price is 133.54% higher than its 52-week low of $1.64 where as its distance from 52-week high of $5.88 is -34.86%.

How many employees does IOVA have?

Number of IOVA employees currently stands at 838.

Link for IOVA official website?

Official Website of IOVA is: https://www.iovance.com

How do I contact IOVA?

IOVA could be contacted at phone 650 260 7120 and can also be accessed through its website. IOVA operates from 825 Industrial Road, San Carlos, CA 94070, United States.

How many shares of IOVA are traded daily?

IOVA stock volume for the day was 45.9M shares. The average number of IOVA shares traded daily for last 3 months was 11.14M.

What is the market cap of IOVA currently?

The market value of IOVA currently stands at $1.27B with its latest stock price at $3.83 and 331.69M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	838
Beta	0.78
Sales or Revenue	$1.19M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

IOVA Company Profile and Key Details

Iovance Biotherapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook